CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Berlin, Germany and 199 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Berlin, Germany and 516 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Berlin, Germany and 108 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Berlin, Germany and 505 other locations
to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...
Phase 3
Berlin, Germany and 117 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Berlin, Germany and 192 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Berlin, Germany and 360 other locations
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...
Phase 1
Berlin, Other, Germany and 23 other locations
cancers.* Part D will find out if and how much SGN-B7H4V can be given with pembrolizumab.* Part E will use the amount found in Part D to fi ...
Phase 1
Berlin, Other, Germany and 18 other locations
Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...
Phase 3
Berlin, Germany and 162 other locations
Clinical trials
Research sites
Resources
Legal